Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $381.44 Average Price Target from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given an average rating of “Hold” by the eleven research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $381.44.

Separately, Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armis Advisers LLC purchased a new position in shares of Medpace in the fourth quarter worth about $278,000. Ascent Group LLC raised its position in Medpace by 16.8% during the 4th quarter. Ascent Group LLC now owns 9,374 shares of the company’s stock worth $3,114,000 after buying an additional 1,349 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Medpace during the 4th quarter valued at approximately $217,000. Palisades Investment Partners LLC boosted its holdings in shares of Medpace by 9.2% in the 4th quarter. Palisades Investment Partners LLC now owns 15,919 shares of the company’s stock valued at $5,289,000 after acquiring an additional 1,338 shares during the last quarter. Finally, Novem Group acquired a new stake in shares of Medpace in the fourth quarter worth $718,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Up 2.2 %

MEDP opened at $332.81 on Monday. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a fifty day moving average price of $341.10 and a 200-day moving average price of $342.93. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts forecast that Medpace will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.